ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
16 oct. 2023 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
18 sept. 2023 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...